

**Table 7.6b**  
**Immunosuppression Use for Induction by Discharge Regimen, 2005 to 2009**  
**Recipients with Pancreas After Kidney (PAK) Transplants**

	Discharge Regimen (w/ or w/o Steroids Use)										All
	CyA	Tac	CyA+ MMF	Tac+ MMF	CyA+ Aza	Tac+ Aza	Siro+ MMF	CyA+ Siro	Tac+ Siro	Other	
<b>Functioning Graft with Immunosuppression Info at Discharge</b>	2	37	34	901	1	6	9	16	45	100	1,151
<b>% of All Regimens</b>	0.2%	3.2%	3.0%	78.3%	0.1%	0.5%	0.8%	1.4%	3.9%	8.7%	100.0%
<b>Induction Drug</b>											
Atgam/NRATG/NRATS	0.0%	0.0%	0.0%	1.6%	0.0%	0.0%	0.0%	0.0%	0.0%	2.0%	1.4%
OKT3	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	2.0%	0.6%
Thymoglobulin	100.0%	24.3%	79.4%	56.0%	100.0%	66.7%	77.8%	100.0%	33.3%	131.0%	62.3%
Zenapax	0.0%	2.7%	2.9%	4.2%	0.0%	0.0%	0.0%	0.0%	0.0%	9.0%	4.3%
Simulect	0.0%	8.1%	2.9%	5.5%	0.0%	0.0%	11.1%	0.0%	8.9%	11.0%	6.1%
Campath	0.0%	43.2%	14.7%	12.9%	0.0%	16.7%	11.1%	0.0%	35.6%	28.0%	15.9%
<b>No Induction Drugs Recorded</b>	0.0%	27.0%	8.8%	21.4%	0.0%	16.7%	11.1%	0.0%	24.4%	9.0%	19.8%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.